As oral GLP-1 pills move from novelty to crowded field, conveglipron is one of the lesser-known names in the race. Developed under the code name HDM1002 by the Chinese pharmaceutical company Huadong Medicine, it's a small-molecule drug designed to be swallowed rather than injected — part of the same wave of development that produced Eli Lilly's orforglipron (Foundayo), AstraZeneca's elecoglipron, and Structure Therapeutics' aleniglipron.
How It's Supposed to Work
Conveglipron is described in the scientific literature as a selective, highly potent full agonist of the GLP-1 receptor — the same receptor that injectable drugs like semaglutide and liraglutide target, and the same receptor orforglipron and the other oral candidates target. Agonists at this receptor slow stomach emptying, increase insulin release in response to meals, and reduce appetite, which is the basic mechanism behind every GLP-1 drug's effect on blood sugar and body weight. In animal studies, conveglipron produced antihyperglycemic (blood-sugar-lowering) and antiobesity effects consistent with that mechanism.
Where It Stands in Human Testing
Conveglipron's clinical story is still being written. The compound's discovery was first presented publicly at the European Association for the Study of Diabetes (EASD) Annual Meeting in October 2023. A first-in-human study — testing escalating single oral doses in healthy volunteers — was published in the journal Diabetes, Obesity & Metabolism in October 2025. As of a January 2026 clinical-trial-tracking update, conveglipron's development program spans three separate indications at three different stages: Phase 3 testing for type 2 diabetes, Phase 2 testing for obesity, and an earlier Phase 1 program specifically in diabetes mellitus. That spread is a reminder that "Phase 3" doesn't mean a drug is close to approval across the board — it describes where a specific indication's trials stand, and conveglipron's weight-loss program is still a full phase behind its diabetes program.
Regulatory Status: Not Approved, Not Available
Conveglipron is not approved by the FDA or any other major regulator, and it is not legally available for purchase or prescription anywhere outside of registered clinical trials. No regulatory filing has been announced. That puts it well behind orforglipron, which the FDA approved in April 2026, and modestly behind AstraZeneca's elecoglipron and Structure Therapeutics' aleniglipron, both of which have reported Phase 2b data and advanced toward Phase 3. Huadong Medicine has not publicly detailed a timeline for a U.S. regulatory submission, and most of its early disclosures have focused on the Chinese and broader Asian market, where the company is based.
Why It's Worth Tracking Anyway
The crowded field of oral GLP-1 candidates matters for a simple reason: pills are generally cheaper to manufacture and distribute than injectable pens, and a drug that works as well as the injectables but doesn't require refrigeration or needles could meaningfully widen access, particularly outside the U.S. and Europe. Whether conveglipron specifically becomes one of the winners in that race — alongside orforglipron, which already has a multi-year head start — will depend on Phase 3 data for type 2 diabetes that hasn't been reported yet, and on results from the earlier-stage obesity program that could still go either way.
As with every investigational drug covered on this site, there is nothing here to act on personally: conveglipron cannot legally be prescribed or purchased in the United States, and no patient should seek it out from a research-chemical vendor. If you're interested in currently available GLP-1 options, that conversation belongs with a licensed physician who can review your own medical history.